274 publications
Name | Date | Type | Actions |
---|---|---|---|
Vétoquinol enters the indian market June 29, 2009 (Lure, France) – Vétoquinol today announced the signing of an agreement for the acquisition of the Animal Health Division of Wockhardt Limited, based in Mumbaï, India. |
29/06/2009 | Public releases | |
Growth in Revenues in the first half of 2009 Vétoquinol’s revenues in the first half of 2009 totalled EUR 119.9 million, an increase of 2.7% compared to the first half of the preceding year. |
16/07/2009 | Public releases | |
Vétoquinol completes the acquisition of Wockhardt Animal Health in India August 20, 2009 (Lure, France) – Vétoquinol today announced the completion of its acquisition of the animal health business division of Wockhardt Limited, based in Mumbaï, India. This acquisition was the subject of an agreement signed with the Wockhardt Limited group on June 26. |
20/08/2009 | Public releases | |
Vétoquinol posts resilient results in the first half of 2009 and continues to pursue its international growth The Board of Directors of Vétoquinol, meeting on August 27, reviewed the group’s business and approved the group’s interim 2009 financial statements. |
31/08/2009 | Public releases | |
Strong growth in Revenues in the 3rd quarter Vétoquinol recorded strong growth in the 3rd quarter of 2009, despite an unfavourable exchange rate effect. The strength in sales was due to a combination of the contribution of acquisitions in Italy and India and sustained organic growth. |
14/10/2009 | Public releases | |
Matthieu Frechin named Managing Director of Vétoquinol December 14, 2009 (Lure, France) – The Board of Directors of Vétoquinol, at its December 10 |
15/12/2009 | Public releases | |
VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success. |
14/01/2010 | Public releases | |
Strong growth in 2009 Revenues: +7.6% January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions. |
20/01/2010 | Public releases | |
Redemption of tranche A bonds February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds. |
26/02/2010 | Public releases | |
2009 annual earnings March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements. |
31/03/2010 | Public releases |